Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy.
Hansol LeeAngela L FergusonCamelia QuekIsmael A VergaraInes Pires daSilvaRuth O AllenTuba Nur GideJordan W ConwayLambros T KoufariotisNicholas K HaywardNicola WaddellMatteo S CarlinoAlexander M MenziesRobyn P M SawElena ShklovskayaHelen RizosSerigne N LôRichard A ScolyerGeorgina V LongUmaimainthan PalendiraJames S WilmottPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Our data demonstrates that tumor environments enriched with CD16+ macrophages are favorable for response to combination anti-PD-1 and anti-CTLA-4 therapy but not anti-PD-1 monotherapy. This data provides a potential biomarker of response for combination immunotherapies in patients with metastatic melanoma.